barusiban Report issue

Small molecule Experimental
AACT ChEMBL DrugBank PubChem

Active Ingredient History

NOW
  • Now
Barusiban (INN) is a non-peptide drug which is among the most potent and selective oxytocin receptor antagonists known. It was trialed by Ferring Pharmaceuticals as a treatment of preterm labor but failed to demonstrate effectiveness and was not pursued any further.   Wikipedia

Chemistry

  • SMILES: CC[C@@H](C)[C@@H]1NC(=O)[C@@H](NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)CCSCC[C@H](NC(=O)[C@H](CC(=O)N)NC1=O)C(=O)N(C)[C@H](CO)CCCN)[C@@H](C)CC
  • InChIKey: UGNGRKKDUVKQDF-IHOMMZCZSA-N
  • Mol. Mass: 830.07
  • ALogP: 0.19
  • ChEMBL Molecule:
    barusiban  
More Chemistry

Pharmacology

Alternative names

barusiban | fe200440 | fe-200440

Organizations (1)

Research & Development (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (4)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (4)


 

Fertilization in Vitro (Phase 2)

Infertility (Phase 2)

Obstetric Labor, Premature (Phase 2)

Premature Birth (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 4
  • # of Trial Organizations: 1

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue